
Elamipretide (SS-31)
Elamipretide (Forzinity) is approved only for Barth syndrome, a rare inherited mitochondrial disease, under accelerated approval based on knee muscle strength in a 12-patient program; a confirmatory trial is under way. It did not improve walking distance or fatigue in the randomized part of that program, and trials in more common conditions (primary mitochondrial myopathy, heart failure, dry macular degeneration) missed their main goals. There is no trial showing it slows aging or extends life.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
People with genetically confirmed Barth syndrome who weigh at least 30 kg, treated by a specialist with a prescription
Common dosing range
Set by your prescriber. The label dose is 40 mg injected under the skin once daily (20 mg once daily in adults with severe kidney impairment not on dialysis)
When to expect effects
Knee strength gains were seen in the open-label extension, from about 12 weeks onward; none were seen in the 12-week randomized phase
Watch out for
No boxed warning. Serious allergic reactions have been reported and rule out further use; injection-site reactions are very common; it contains benzyl alcohol and is not for newborns. It is approved only for Barth syndrome: products sold as "SS-31" for longevity are unapproved and unverified
What is it
Elamipretide (also called SS-31, and in early trials MTP-131 or Bendavia) is a small peptide given as an injection under the skin. It is FDA-approved under the brand name Forzinity (Stealth BioTherapeutics) for one use only: to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Barth syndrome is a rare, X-linked genetic disease of the mitochondria, the parts of cells that make energy. FDA granted accelerated approval on September 19, 2025, based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, and the label says continued approval may be contingent on a confirmatory trial; FDA required a randomized, placebo-controlled trial in patients 5 years and older, and a 72-week placebo-controlled trial is recruiting. Elamipretide is not approved for aging, "longevity", energy or any other mitochondrial condition. In larger trials in primary mitochondrial myopathy, heart failure and dry macular degeneration it did not meet its main goals, and in published trials in healthy older adults it has only been given as a single dose. Vials sold online as "SS-31" for research are not Forzinity and are not FDA-approved.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
walking and fatigue in primary mitochondrial myopathy Good Evidence | 6-minute walk -3.2 m versus placebo (95% CI -18.7 to 12.3); no change in fatigue | None shown in this trial | No benefit at 24 weeks |
muscle strength and walking in Barth syndrome Limited Evidence | Median knee strength +63 newtons at week 168 in 8 patients (no control group); no difference from placebo in the 12-week randomized phase | People with genetically confirmed Barth syndrome aged 12 and older weighing at least 30 kg | Strength gains appeared from about 12 weeks into the open-label extension |
heart function in heart failure with reduced ejection fraction Limited Evidence | No difference from placebo in heart volume or ejection fraction at 4 weeks | None shown in this trial | No benefit at 4 weeks |
vision and lesion growth in dry age-related macular degeneration Limited Evidence | Primary endpoints not met; secondary ellipsoid zone loss 43% slower (nominal) | Under study in dry macular degeneration in the ongoing phase 3 trial | Not established |
muscle energy production in older adults (the basis of "longevity" use) Mixed Evidence | Short-lived rise in muscle ATP production after one infusion; no change in fatigue resistance | Research participants only | Immediately after one infusion; gone by day 7 |
walking and fatigue in primary mitochondrial myopathy
- Effect
- 6-minute walk -3.2 m versus placebo (95% CI -18.7 to 12.3); no change in fatigue
- Best fit
- None shown in this trial
- Time
- No benefit at 24 weeks
muscle strength and walking in Barth syndrome
- Effect
- Median knee strength +63 newtons at week 168 in 8 patients (no control group); no difference from placebo in the 12-week randomized phase
- Best fit
- People with genetically confirmed Barth syndrome aged 12 and older weighing at least 30 kg
- Time
- Strength gains appeared from about 12 weeks into the open-label extension
heart function in heart failure with reduced ejection fraction
- Effect
- No difference from placebo in heart volume or ejection fraction at 4 weeks
- Best fit
- None shown in this trial
- Time
- No benefit at 4 weeks
vision and lesion growth in dry age-related macular degeneration
- Effect
- Primary endpoints not met; secondary ellipsoid zone loss 43% slower (nominal)
- Best fit
- Under study in dry macular degeneration in the ongoing phase 3 trial
- Time
- Not established
muscle energy production in older adults (the basis of "longevity" use)
- Effect
- Short-lived rise in muscle ATP production after one infusion; no change in fatigue resistance
- Best fit
- Research participants only
- Time
- Immediately after one infusion; gone by day 7
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
walking and fatigue in primary mitochondrial myopathy
No benefit foundMMPOWER-3, a phase 3 trial, randomized 218 adults with genetically confirmed primary mitochondrial myopathy (mean age 45.6, 64% women) to 40 mg daily or placebo for 24 weeks. It did not meet its main goals: the difference in 6-minute walk distance was -3.2 m (95% CI -18.7 to 12.3; p = 0.69), and fatigue scores did not differ (p = 0.37). The drug was well tolerated, with mostly mild to moderate adverse events.
Bottom line: The largest trial of elamipretide in a mitochondrial disease found no improvement in walking or fatigue.
muscle strength and walking in Barth syndrome
Disease adjunctIn the TAZPOWER trial, 12 males aged 12 to 35 with genetically confirmed Barth syndrome took 40 mg daily or placebo for 12 weeks each, in random order, with a 4-week break between. Neither main goal (6-minute walk distance and a fatigue score) improved, and the label reports no increase in knee strength in the randomized phase (median change +4 newtons on elamipretide versus -5 on placebo). Ten patients then took it in an open-label extension. The FDA label reports that, from a median starting strength of 124 newtons, knee strength rose by a median of 34 newtons at week 12 of the extension and 63 newtons at week 168 (8 patients). In the papers, walk distance improved by 95.9 m at 36 weeks (8 patients) and by a cumulative 96.1 m at week 168. The extension had no placebo group, the numbers are very small, the manufacturer funded the trial and helped design it and analyze the data, and one author was a company employee. FDA accepted knee strength as an intermediate endpoint for accelerated approval and required a confirmatory randomized trial.
Bottom line: Strength and walking improved over years of open-label use, but the randomized phase showed no benefit, so the confirmatory trial matters.
Evidence is mixed
In the double-blind, placebo-controlled phase, elamipretide was not better than placebo on walk distance, fatigue or knee strength. The improvements come from the uncontrolled extension, where expectation and practice effects cannot be ruled out.
heart function in heart failure with reduced ejection fraction
No benefit foundThe PROGRESS-HF phase 2 trial randomized 71 adults with stable heart failure (ejection fraction 40% or less, mean age 65) to placebo, 4 mg or 40 mg daily for 28 days. Heart volume on MRI (left ventricular end-systolic volume) did not change compared with placebo (40 mg versus placebo: difference 2.3 mL, 95% CI -1.9 to 6.5; P = 0.28), and neither did ejection fraction. Side effects were similar across groups.
Bottom line: Four weeks of elamipretide did not improve heart structure or pumping in heart failure.
vision and lesion growth in dry age-related macular degeneration
No benefit foundIn the ReCLAIM-2 phase 2 trial, 176 people aged 55 or older with dry macular degeneration and geographic atrophy (after a protocol change, only atrophy away from the center of vision; 27 people with central atrophy had already joined) took 40 mg daily or placebo for 48 weeks. Neither main goal improved: low-light visual acuity and growth of the atrophy area were not significantly different from placebo. In secondary analyses, loss of a light-sensing retinal layer (the ellipsoid zone) progressed 43% less (nominal P = 0.0034), and more people gained 10 or more letters in low light (14.6% versus 2.1%), but these were not the trial's main tests. Adverse events occurred in 86% on elamipretide and 71% on placebo, mostly injection-site reactions. A phase 3 trial is ongoing.
Bottom line: It missed its main vision goals; a hint on a retinal scan measure is being tested in a phase 3 trial.
Evidence is mixed
The secondary retinal-layer and letter-gain results favored elamipretide, but the primary endpoints were not met, so these signals need confirmation.
muscle energy production in older adults (the basis of "longevity" use)
Biomarker supportIn this randomized, placebo-controlled trial, 39 healthy adults aged 60 to 85 (46% women), chosen because their muscle mitochondria worked poorly, received a single 2-hour intravenous infusion of elamipretide or placebo. Right after the infusion, the maximum energy (ATP) production of a hand muscle rose compared with placebo (P = 0.045 for percent change), but the effect was gone at day 7, and the muscle did not resist fatigue any better. The manufacturer funded the work and worked with the authors on its design, and three authors had been paid consultants to the company from 2014 to 2016. A 4-week safety study of daily injections in 30 adults aged 65 to 80 is recruiting. No trial has tested whether elamipretide improves strength, function, disease or lifespan in aging people.
Bottom line: One infusion briefly changed a lab measure of muscle energy in older adults; there is no evidence that it slows aging.
How it works
How to take it
What to track
Bottom line: A daily injection for Barth syndrome only; your prescriber sets the dose, and it is not an anti-aging product.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Serious allergic (hypersensitivity) reactions needing emergency care have been reported, including skin reactions and breathing symptoms such as cough. They can start within minutes or months after starting. After a serious reaction, the label says not to give it again. There is no boxed warning on the label.
Benzyl alcohol toxicity in newborns. Forzinity contains benzyl alcohol as a preservative (20 mg per mL), which has caused serious and fatal reactions (gasping syndrome) in low birth weight and premature babies given benzyl alcohol drugs into a vein. It is not approved for newborns or for intravenous use.
Limited safety data. The label's safety data come from 12 male patients aged 12 to 35, followed for up to 192 weeks, and no one aged 65 or older with Barth syndrome was studied. Overdose symptoms are expected to be histamine-related, such as low blood pressure and feeling faint.
Unapproved "SS-31" products. FDA approved one elamipretide product, Forzinity, made by Stealth BioTherapeutics. Products sold under the name SS-31 outside a prescription are not that product, and compounded drugs are not FDA-approved, so FDA does not check their safety, effectiveness or quality before they are sold.
Who should avoid it
- People who have had a serious allergic reaction to elamipretide or any ingredient in Forzinity (contraindicated)
- Newborns, because of the benzyl alcohol preservative; safety and effectiveness are also not established in children under 30 kg
- People on dialysis, unless a specialist decides otherwise: the label says there is not enough information to recommend a dose
- People without Barth syndrome who want it for aging, energy or performance: it is approved only for Barth syndrome, and trials in other conditions did not meet their main goals
Pregnancy & breastfeeding
Pregnancy: the label says there are no data on use in pregnant women, because Barth syndrome is an X-linked disease that is not likely to affect females. Animal studies in rats and rabbits found no harm to development at exposures up to about 4 to 10 times the human dose, and benzyl alcohol is unlikely to reach the fetus. Breastfeeding: the label says there are no data on whether it passes into breast milk or affects a breastfed baby or milk production, and benzyl alcohol exposure through milk is unlikely. Decisions go to your doctor.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is elamipretide FDA-approved?⌄
Yes, for one use. FDA granted accelerated approval to Forzinity (elamipretide) on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. The approval is based on knee muscle strength, and FDA requires a randomized, placebo-controlled trial to confirm that patients benefit. It is not approved for any other condition.
Does elamipretide (SS-31) work for longevity or anti-aging?⌄
That has not been shown, and it is not approved for these uses. The published randomized trial in healthy older adults gave a single infusion and found a short-lived rise in a lab measure of muscle energy, with no change in muscle fatigue. Trials in mitochondrial myopathy, heart failure and dry macular degeneration did not meet their main goals. A small safety study of daily injections in people aged 65 to 80 is recruiting. Ask your doctor about approved ways to address the problem you are trying to solve.
Is the "SS-31" sold online the same as Forzinity?⌄
No. Forzinity is the only FDA-approved elamipretide product. Vials or sprays sold online as SS-31 for research are not checked by FDA for identity, purity, dose or sterility, and their labels often say they are not for human use.
Can I take elamipretide with my supplements or other medicines?⌄
There are no studies of elamipretide with supplements. In lab tests it did not block or speed up the main liver enzymes that break down other drugs, and in studies with aspirin, clopidogrel and heparin it did not change how those drugs worked. In lab tests it blocked a kidney transporter called MATE1, and the label does not say whether this matters for other medicines. Ask your doctor or pharmacist to check your full list.
What are the main side effects?⌄
Injection-site reactions such as redness, pain, hardening, itching, bruising and hives are very common. Eosinophil counts on blood tests often rise for a few months. Serious allergic reactions have been reported: get emergency care for trouble breathing, swelling or widespread rash.
Why was it approved if the trial missed its main goals?⌄
In the 12-week randomized phase, elamipretide did not beat placebo on walk distance or fatigue. FDA granted accelerated approval because knee strength improved during long-term open-label use, a measure it considered reasonably likely to predict benefit such as easier standing or longer walking. The label says continued approval may be contingent on a confirmatory trial; a 72-week placebo-controlled study is recruiting.
References by claim
muscle strength and walking in Barth syndrome
walking and fatigue in primary mitochondrial myopathy
Karaa et al., 2023 · PMC (2023) link
heart function in heart failure with reduced ejection fraction
Butler et al., 2020 · PubMed (2020) link
vision and lesion growth in dry age-related macular degeneration
Ehlers et al., 2025 · PMC (2025) link
muscle energy production in older adults (the basis of "longevity" use)
Roshanravan et al., 2021 · PMC (2021) link
Track Elamipretide (SS-31) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
